Europe Biosimilars Market Forecast to 2030 - Regional Analysis By Disease Indication, Route of Administration, Drug Class, Distribution Channel, and Region

List of Tables

The Europe biosimilars market is expected to grow from US$ 10,344.86 million in 2022 to US$ 1,15,125.91 million by 2030; it is estimated to grow at a CAGR of 35.1% from 2022 to 2030.

The report highlights trends prevailing in the market and factors driving the market growth. The market growth is attributed to the increasing prevalence of chronic diseases and rising approvals of biosimilars. Additionally, collaborations for biosimilars and clinical trials is likely to emerge as a significant trend in the market during the forecast period. However, high cost involvement and complexities in biosimilar product manufacturing hinders market growth during the forecast period 2022-2030.

Collaborations for Biosimilars and Clinical Trials Drives the Europe Biosimilars Market

Joint ventures and other collaboration models will help biosimilar medicine manufacturers maintain a competitive edge over rivals in the market in the coming years.

By collaborating with other companies planning to research, launch, and market biosimilar drugs, biosimilar manufacturers can develop their products rapidly and launch products effectively in a way that overcomes patent risks and gains clinician and patient confidence in the product. Product development can be expedited by gaining local and foreign expertise, development platform access, and research and clinical trial funding.

Collaborating with a bigger biopharmaceutical manufacturer allows access to established manufacturing facilities. The collaboration can be done for outsourcing activities such as cell line development, biologics and biosimilar manufacturing, process scaling, and any required technology transfer.

There are long-term benefits from collaborations. They can make it easy to tender for future biosimilar production projects within the country and offer early and efficient product development and market penetration. In a sizeable market such as Europe, which has significant country-level diversity in healthcare policies and market dynamics, access to local knowledge obtained through such collaborations can also prove invaluable.

The immense potential of the biosimilars market has led to many recent, high-profile collaborations. A few instances are given below:

In June 2023, Samsung Biologics announced a strategic partnership with Pfizer for the long-term commercial manufacturing of Pfizer's multi-product portfolio. The agreement aims that Samsung Biologics will offer Pfizer additional capacity for large-scale manufacturing of a multi-product biosimilar portfolio encompassing oncology, inflammation, and immunology.

In May 2023, Sandoz, a Novartis division, announced a biosimilar collaboration with Evotec Biologics. The agreement covers developing and manufacturing multiple biosimilar medicines intended for rapid development and the subsequent manufacturing of multiple biosimilars. The development of biosimilars at the Evotec Biologics facility will ramp up under the collaboration in the next 12-18 months.

Thus, collaborations of manufacturers for biosimilar production and clinical trials will be the key trend in the biosimilar market during the forecast period.

Patent Expiry of Blockbuster Biologics Offers Lucrative Market Opportunity

Biologicals represent promising new therapies for previously incurable diseases and are becoming highly important in the pharmaceuticals market. However, patents for originator biologicals are expected to expire in the coming years.

Estimated patent and exclusivity expiry dates for best-selling biologicals are given in the following table .

Biologicals Expiry Month & Years

Avastin January 2022

Cyramza May 2023

Adcetris August 2023

Abthrax October 2024

Gazyva/Gazyvaro November 2024

Darzalex May 2026

Ocrevus April 2027

Emgality September 2028

Hemlibra February 2028

Llumetri March 2028

Imfinzi September 2028

Mylotarg April 2028

Imfinzi September 2028

Mylotarg April 2028

Sylvant July 2034

Source: Generics and Biosimilars Initiative (GaBI) Journal

The patent expiration and other intellectual property rights for originator biologicals will create a need to introduce new biosimilars in the future. As a result, competition among market players will surge in the industry in the coming years. Thus, the patent expiry of blockbuster biologics is expected to create lucrative opportunities for the biosimilar market during the forecast period.

Germany holds largest market share for the Europe biosimilars market from 2022-2030. Biosimilars introduce competition and increase the affordability of biologics, which ultimately deliver savings and value-added services to support patient care and the healthcare community. Healthcare professionals can treat more patients with high-quality biologics while reducing spending. For example, in Germany, according to Sandoz, the number of daily therapeutic doses of an anti-TNF medicine increased by 29% (from 17.18 to 22.18 million) after introducing biosimilars in 2022.

Germany has achieved acceptance of biosimilars with payers, providers, and patients as an integral part of appropriate medicine use. There is full reimbursement from a price set by the company, including immediate patient access to biosimilars. The structure of hospital tendering by multiple buying groups and separate hospital chains allows for competition among manufacturers to be maintained in Germany. For instance, in November 2018, the German Health Ministry introduced a draft bill on safety in the supply of pharmaceuticals. The Gesetz fur Mehr Sicherheit in der Arzneimittelversor-gung (GSAV) bill aims to provide a legal framework for the automatic substitution of biosimilars by pharmacists in Germany.

Due to the huge potential for cost savings, the German Health Ministry introduced a new law to increase the adoption of biosimilars. As few European Union (EU) countries allow pharmacist substitution of biosimilars, this would represent a significant change in practice, particularly for Germany. Additionally, in Germany, a law passed in 2019 foresees the automatic substitution of biosimilars in pharmacies beginning in 2022, provided the Federal Joint Committee (the highest decision-making body of the self-governance of health insurers and providers) has determined the interchangeability of the medicines in question, and the prescribing physician has not explicitly excluded it. Therefore, with the growing government initiatives for adopting biosimilars in Germany, the market is expected to grow.

Various organic and inorganic strategies are adopted by companies in the Europe biosimilars market. The organic strategies mainly include product launches and product approvals. Further, inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help the market players strengthen their customer base and expand their product portfolios. A few of the significant developments by key players in the Europe biosimilars market are listed below.

International Diabetes Federation, European Medicine Agency, Centers for Disease Control and Prevention, Chinese Clinical Oncology, National Comprehensive Care Network are a few of the major primary and secondary sources referred to while preparing the report on the Europe biosimilars market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe biosimilars market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global Europe biosimilars market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

Product Code: TIPRE00030025

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Europe Biosimilars Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Biosimilars Market - Market Landscape

4.1 Overview
- 4.1.1 Europe PEST Analysis
4.2 Actual Market Price/Net Price
- 4.2.1 France
- 4.2.2 Germany
- 4.2.3 Italy
- 4.2.4 Spain
- 4.2.5 UK

5. Europe Biosimilars Market

5.1 Market Drivers
- 5.1.1 Increasing Prevalence of Chronic Diseases
- 5.1.2 Rising Approvals of Biosimilars
5.2 Market Restraints
- 5.2.1 High Cost Involvement and Complexities in Biosimilar Product Manufacturing
5.3 Market Opportunities
- 5.3.1 Patent Expiry of Blockbuster Biologics
5.4 Future Trends
- 5.4.1 Collaborations for Biosimilars and Clinical Trials
5.5 Impact analysis

6. Europe Biosimilars Market - Regional Analysis

6.1 Europe Biosimilars Market Revenue Forecast and Analysis

7. Europe Biosimilars Market - Revenue and Forecast to 2030 - by Disease Indication

7.1 Overview
7.2 Europe Biosimilars Market Revenue Share, by Type 2022 & 2030 (%)
7.3 Cancer
- 7.3.1 Overview
- 7.3.2 Cancer: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Diabetes
- 7.4.1 Overview
- 7.4.2 Diabetes: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Autoimmune Diseases
- 7.5.1 Overview
- 7.5.2 Autoimmune Diseases: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 7.5.3 Psoriasis
  - 7.5.3.1 Overview
- 7.5.4 Psoriasis: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 7.5.5 Arthritis
  - 7.5.5.1 Overview
- 7.5.6 Arthritis: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 7.5.7 Others
  - 7.5.7.1 Overview
  - 7.5.7.2 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Other Disease Indication
- 7.6.1 Overview
- 7.6.2 Other Disease Indication: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Biosimilars Market Analysis and Forecasts to 2028 - by Route of Administration

8.1 Overview
8.2 Europe Biosimilars Market, by Route of Administration 2022 & 2030 (%)
8.3 Intravenous
- 8.3.1 Overview
- 8.3.2 Intravenous: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Subcutaneous
- 8.4.1 Overview
- 8.4.2 Subcutaneous: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
- 8.5.1 Overview
- 8.5.2 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Biosimilars Market - Revenue and Forecast to 2030 - by Drug Class

9.1 Overview
9.2 Europe Biosimilars Market Revenue Share, by Drug Class 2022 & 2030 (%)
9.3 Granulocyte Colony-Stimulating Factor
- 9.3.1 Overview
- 9.3.2 Granulocyte Colony-Stimulating Factor: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Insulin
- 9.4.1 Overview
- 9.4.2 Insulin: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
9.5 TNF Blockers and Monoclonal Antibodies
- 9.5.1 Overview
- 9.5.2 TNF Blockers and Monoclonal Antibodies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
9.6 Others
- 9.6.1 Overview
- 9.6.2 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Biosimilars Market - Revenue and Forecast to 2030 - by Distribution Channel

10.1 Overview
10.2 Europe Biosimilars Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
10.3 Endocrinologists
- 10.3.1 Overview
10.4 Immunologists
- 10.4.1 Overview
10.5 Rheumatologists
- 10.5.1 Overview
10.6 Oncologists
- 10.6.1 Overview
10.7 Dermatologists
- 10.7.1 Overview
10.8 Retina Compounding
- 10.8.1 Overview
10.9 Others
- 10.9.1 Overview
10.10 Hospital Pharmacies
- 10.10.1 Overview
- 10.10.2 Hospital Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.3 Endocrinologists
  - 10.10.3.1 Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.4 Immunologists
  - 10.10.4.1 Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.5 Rheumatologists
  - 10.10.5.1 Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.6 Oncologists
  - 10.10.6.1 Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.7 Dermatologists
  - 10.10.7.1 Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.8 Retina Specialists
  - 10.10.8.1 Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.9 Others
  - 10.10.9.1 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
10.11 Compounding Pharmacies
- 10.11.1 Overview
- 10.11.2 Compounding Pharmacies : Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.3 Endocrinologists
  - 10.11.3.1 Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.4 Immunologists
  - 10.11.4.1 Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.5 Rheumatologists
  - 10.11.5.1 Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.6 Oncologists
  - 10.11.6.1 Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.7 Dermatologists
  - 10.11.7.1 Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.8 Retina Specialists
  - 10.11.8.1 Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.9 Others
  - 10.11.9.1 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
10.12 Retail Pharmacies
- 10.12.1 Overview
- 10.12.2 Retail Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.3 Endocrinologists
  - 10.12.3.1 Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.4 Immunologists
  - 10.12.4.1 Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.5 Rheumatologists
  - 10.12.5.1 Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.6 Oncologists
  - 10.12.6.1 Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.7 Dermatologists
  - 10.12.7.1 Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.8 Retina Specialists
  - 10.12.8.1 Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.9 Others
  - 10.12.9.1 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
10.13 Online Pharmacies
- 10.13.1 Overview
- 10.13.2 Online Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.3 Endocrinologists
  - 10.13.3.1 Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.4 Immunologists
  - 10.13.4.1 Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.5 Rheumatologists
  - 10.13.5.1 Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.6 Oncologists
  - 10.13.6.1 Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.7 Dermatologists
  - 10.13.7.1 Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.8 Retina Specialists
  - 10.13.8.1 Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.9 Others
  - 10.13.9.1 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)

11. Europe Biosimilars Market - Revenue and Forecast to 2030 - Geographic Analysis

11.1 Europe Biosimilars Market, Revenue and Forecast to 2030
- 11.1.1 Overview
- 11.1.2 Europe Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
  - 11.1.2.1 Europe Biosimilars Market, by Disease Indication
  - 11.1.2.2 Europe Biosimilars Market, by Autoimmune Diseases
  - 11.1.2.3 Europe Biosimilars Market, by Route of Administration
  - 11.1.2.4 Europe Biosimilars Market, by Drug Class
  - 11.1.2.5 Europe Biosimilars Market, by Distribution Channel
  - 11.1.2.6 Europe Biosimilars Market, by Hospital Pharmacies
  - 11.1.2.7 Europe Biosimilars Market, by Compounding Pharmacies
  - 11.1.2.8 Europe Biosimilars Market, by Retail Pharmacies
  - 11.1.2.9 Europe Biosimilars Market, by Online Pharmacies
  - 11.1.2.10 Europe Biosimilars Market by Country
    - 11.1.2.10.1 Germany
    - 11.1.2.10.1.1 Overview
    - 11.1.2.10.1.2 Germany Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.10.1.2.1 Germany Biosimilars Market, by Disease Indication
    - 11.1.2.10.1.2.2 Germany Biosimilars Market, by Autoimmune Diseases
    - 11.1.2.10.1.2.3 Germany Biosimilars Market, by Route of Administration
    - 11.1.2.10.1.2.4 Germany Biosimilars Market, by Drug Class
    - 11.1.2.10.1.2.5 Germany Biosimilars Market, by Distribution Channel
    - 11.1.2.10.1.2.6 Germany Biosimilars Market, by Hospital Pharmacies
    - 11.1.2.10.1.2.7 Germany Biosimilars Market, by Compounding Pharmacies
    - 11.1.2.10.1.2.8 Germany Biosimilars Market, by Retail Pharmacies
    - 11.1.2.10.1.2.9 Germany Biosimilars Market, by Online Pharmacies
    - 11.1.2.10.2 UK
    - 11.1.2.10.3 Overview
    - 11.1.2.10.3.1 UK Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.10.3.1.1 UK Biosimilars Market, by Disease Indication
    - 11.1.2.10.3.1.2 UK Biosimilars Market, by Autoimmune Diseases
    - 11.1.2.10.3.1.3 UK Biosimilars Market, by Route of Administration
    - 11.1.2.10.3.1.4 UK Biosimilars Market, by Drug Class
    - 11.1.2.10.3.1.5 UK Biosimilars Market, by Distribution Channel
    - 11.1.2.10.3.1.6 UK Biosimilars Market, by Hospital Pharmacies
    - 11.1.2.10.3.1.7 UK Biosimilars Market, by Compounding Pharmacies
    - 11.1.2.10.3.1.8 UK Biosimilars Market, by Retail Pharmacies
    - 11.1.2.10.3.1.9 UK Biosimilars Market, by Online Pharmacies
    - 11.1.2.10.4 France
    - 11.1.2.10.4.1 Overview
    - 11.1.2.10.4.2 France Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.10.4.2.1 France Biosimilars Market, by Disease Indication
    - 11.1.2.10.4.2.2 France Biosimilars Market, by Autoimmune Diseases
    - 11.1.2.10.4.2.3 France Biosimilars Market, by Route of Administration
    - 11.1.2.10.4.2.4 France Biosimilars Market, by Drug Class
    - 11.1.2.10.4.2.5 France Biosimilars Market, by Distribution Channel
    - 11.1.2.10.4.2.6 France Biosimilars Market, by Hospital Pharmacies
    - 11.1.2.10.4.2.7 France Biosimilars Market, by Compounding Pharmacies
    - 11.1.2.10.4.2.8 France Biosimilars Market, by Retail Pharmacies
    - 11.1.2.10.4.2.9 France Biosimilars Market, by Online Pharmacies
    - 11.1.2.10.5 Italy
    - 11.1.2.10.5.1 Overview
    - 11.1.2.10.5.2 Italy Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.10.5.2.1 Italy Biosimilars Market, by Disease Indication
    - 11.1.2.10.5.2.2 Italy Biosimilars Market, by Autoimmune Diseases
    - 11.1.2.10.5.2.3 Italy Biosimilars Market, by Route of Administration
    - 11.1.2.10.5.2.4 Italy Biosimilars Market, by Drug Class
    - 11.1.2.10.5.2.5 Italy Biosimilars Market, by Distribution Channel
    - 11.1.2.10.5.2.6 Italy Biosimilars Market, by Hospital Pharmacies
    - 11.1.2.10.5.2.7 Italy Biosimilars Market, by Compounding Pharmacies
    - 11.1.2.10.5.2.8 Italy Biosimilars Market, by Retail Pharmacies
    - 11.1.2.10.5.2.9 Italy Biosimilars Market, by Online Pharmacies
    - 11.1.2.10.6 Spain
    - 11.1.2.10.6.1 Overview
    - 11.1.2.10.6.2 Spain Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.10.6.2.1 Spain Biosimilars Market, by Disease Indication
    - 11.1.2.10.6.2.2 Spain Biosimilars Market, by Autoimmune Diseases
    - 11.1.2.10.6.2.3 Spain Biosimilars Market, by Route of Administration
    - 11.1.2.10.6.2.4 Spain Biosimilars Market, by Drug Class
    - 11.1.2.10.6.2.5 Spain Biosimilars Market, by Distribution Channel
    - 11.1.2.10.6.2.6 Spain Biosimilars Market, by Hospital Pharmacies
    - 11.1.2.10.6.2.7 Spain Biosimilars Market, by Compounding Pharmacies
    - 11.1.2.10.6.2.8 Spain Biosimilars Market, by Retail Pharmacies
    - 11.1.2.10.6.2.9 Spain Biosimilars Market, by Online Pharmacies
    - 11.1.2.10.7 Rest of Europe
    - 11.1.2.10.7.1 Overview
    - 11.1.2.10.7.2 Rest of Europe Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.10.7.2.1 Rest of Europe Biosimilars Market, by Disease Indication
    - 11.1.2.10.7.2.2 Rest of Europe Biosimilars Market, by Autoimmune Diseases
    - 11.1.2.10.7.2.3 Rest of Europe Biosimilars Market, by Route of Administration
    - 11.1.2.10.7.2.4 Rest of Europe Biosimilars Market, by Drug Class
    - 11.1.2.10.7.2.5 Rest of Europe Biosimilars Market, by Distribution Channel
    - 11.1.2.10.7.2.6 Rest of Europe Biosimilars Market, by Hospital Pharmacies
    - 11.1.2.10.7.2.7 Rest of Europe Biosimilars Market, by Compounding Pharmacies
    - 11.1.2.10.7.2.8 Rest of Europe Biosimilars Market, by Retail Pharmacies
    - 11.1.2.10.7.2.9 Rest of Europe Biosimilars Market, by Online Pharmacies

12. Pre and Post COVID-19 Impact

12.1 Pre and Post COVID-19 Impact

13. Biosimilars Market - Industry Landscape

13.1 Overview
13.2 Growth Strategies in Biosimilars Market
13.3 Inorganic Growth Strategies
- 13.3.1 Overview
13.4 Organic Growth Strategies
- 13.4.1 Overview

14. Company Profiles

14.1 Amgen Inc
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Celltrion Inc
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Sanofi SA
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
14.4 Biocon Ltd
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Samsung Bioepis Co Ltd
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Eli Lilly and Co
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Sandoz AG
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Teva Pharmaceutical Industries Ltd
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Pfizer Inc
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 Dr. Reddy's Laboratories Ltd
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments

15. Appendix

15.1 About The Insight Partners
15.2 Glossary of Terms